In a recent article from Medical Device Network they share the exciting news of Biolinq's recent achievement in securing a remarkable $58 million for the advancement of their glucose microsensor pivotal trial. This substantial investment underscores the potential impact of their groundbreaking technology on revolutionising diabetes management worldwide.
In the full article they look at the intricacies of Biolinq's innovative approach and how it promises to transform the landscape of glucose monitoring and the potential upsides for both patients and healthcare providers.
Read the full article here: Biolinq raises $58m for glucose microsensor pivotal trial
📰 Source: Medical Device Network
____________________________________________________________________________________________________________________________________________________________________________________________________
Cure Talent is a recruitment agency dedicated to the medical technology industry. Whether you are looking for a new role in the medical device sector or you’re an innovative medical device, digital health, or biotech company looking for staff, get in touch with the team today and explore how Cure Talent can help!